nCompound: Retatrutide
nCAS Number: 2381089-83-2
nMolecular Formula: C205H320N56O63S2
nPurity: 99.71% (HPLC-UV verified)
nThird-Party Testing: Testides Analytical (independent third-party lab)
nCOA Download: View Full COA (PDF)
nReport: DBAV-RETA-10-062726
nSource: Research grade, third-party tested
nShipping: Same-day shipping from our US facility
n
Retatrutide peptide: a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This investigational research compound is available from Maple Research Labs at 10mg per vial with greater than 99%+ HPLC-verified purity and batch-specific COA.
n
Product Specifications
n
-
n
- Alternative Names: LY-3437943, GGG Tri-Agonist
- Receptor Targets: GLP-1R, GIPR, GCGR
- Purity: >99%+ (HPLC verified)
- Form: Lyophilized powder
- Quantity: 10mg per vial
n
n
n
n
n
n
Retatrutide Peptide Research Summary
n
Retatrutide (LY-3437943) is a synthetic peptide developed as a triple agonist of the GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR). This triple agonist approach distinguishes it from dual agonists such as tirzepatide and single agonists such as semaglutide in preclinical metabolic research.
n
Mechanism of Action Research
n
Retatrutide engages three distinct G protein-coupled receptors with complementary downstream signaling effects studied in preclinical models. Published binding affinity studies have characterized the peptide relative activity at each receptor, with the highest potency reported at the GIPR, followed by GLP-1R and GCGR.
n
All findings referenced are from preclinical research and early-phase investigations. Researchers should consult primary literature for complete experimental protocols.
n
Certificate of Analysis (COA)
n
Testing Laboratory: Testides Analytical. Purity (HPLC-UV): 99.71%. Report: DBAV-RETA-10-062726. Download Full COA (PDF)
n
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Reviews
There are no reviews yet.